ANXA5 and cancer: Most clinical experience has been gained with the radioactive tracers 99 mTc-Annexin V [10,11] and 99 mTc-6-hydrazinonicotinic [HYNIC]-radiolabeled Annexin V, the latter being used in phase II/III trials for determining the efficacy of chemotherapy in cancer patients [1].